EMA starts evaluation of Moderna's booster application

Moderna has applied for the European health authority's approval for the use of its Covid-19 vaccine, Spikevax, as a booster dose in re-vaccination schemes.
Photo: David W Cerny/Reuters/Ritzau Scanpix
Photo: David W Cerny/Reuters/Ritzau Scanpix
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

The European Medicines Agency (EMA) has begun its assessment of data from US-based Moderna, which has applied for the approval of its Spikevax in use as a Covid-19 booster vaccine, the EMA reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading